Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement
Business Wire•20/11/2026•16:30 ET
0
Key Highlights
- ➤Avenzo-Rallybio merger closed November 20; combined company begins Nasdaq trading as AVZO November 23
- ➤$215 million private placement completed; cash expected to fund operations into late 2028
- ➤AVZO-1418 Phase 1 showed 63% objective response rate in 19 evaluable EGFR-mutant NSCLC patients
- ➤Avenzo expects AVZO-103 and AVZO-023 Phase 1 data presentations before year-end 2026
- ➤Rallybio stockholders receive $83.6 million special distribution, or $13.90 per share, November 30
Expert Statements
Athena Countouriotis, Chair, President and Chief Executive Officer of Avenzo Therapeutics
“We are pleased to complete this merger and launch Avenzo as a public company, with a pipeline of four potentially best-in-class or first-in-class clinical stage product candidates.”
Athena Countouriotis, Chair, President and Chief Executive Officer of Avenzo Therapeutics
“We are excited by the positive preliminary AVZO-1418 data we presented this week at ENA, and we look forward to two additional clinical data presentations before year-end: initial Phase 1 data for AVZO-103, to be presented by our partner VelaVigo, and updated Phase 1 data for AVZO-023.”
Athena Countouriotis, Chair, President and Chief Executive Officer of Avenzo Therapeutics
“With our strong balance sheet, I believe Avenzo is well positioned to deliver much-needed therapies to patients and create meaningful value for our stakeholders.”
Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement
Merger creates Nasdaq-listed, clinical-stage oncology company; shares expected to begin trading as “AVZO” on November 23, 2026
Get started
Create a free account to read the full story.
